Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

1.

Targeting bone physiology for the treatment of metastatic prostate cancer.

Autio KA, Morris MJ.

Clin Adv Hematol Oncol. 2013 Mar;11(3):134-43. Review.

PMID:
23598981
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Bone targeted therapies in metastatic castration-resistant prostate cancer.

Rajpar S, Fizazi K.

Cancer J. 2013 Jan-Feb;19(1):66-70. doi: 10.1097/PPO.0b013e31827f123e. Review.

PMID:
23337759
[PubMed - indexed for MEDLINE]
3.

Bone metastases in prostate cancer: a targeted approach.

Storey JA, Torti FM.

Curr Opin Oncol. 2007 May;19(3):254-8. Review.

PMID:
17414645
[PubMed - indexed for MEDLINE]
4.

Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.

Loberg RD, Logothetis CJ, Keller ET, Pienta KJ.

J Clin Oncol. 2005 Nov 10;23(32):8232-41. Review.

PMID:
16278478
[PubMed - indexed for MEDLINE]
5.

Current trials using bone-targeting agents in prostate cancer.

Tu SM, Lin SH.

Cancer J. 2008 Jan-Feb;14(1):35-9. doi: 10.1097/PPO.0b013e318161d32d. Review. Erratum in: Cancer J. 2008 May-Jun;14(3):199.

PMID:
18303481
[PubMed - indexed for MEDLINE]
6.

Clinical approaches to osseous metastases in prostate cancer.

Morris MJ, Scher HI.

Oncologist. 2003;8(2):161-73. Review.

PMID:
12697941
[PubMed - indexed for MEDLINE]
Free Article
7.

Recent advances in bone-targeted therapies of metastatic prostate cancer.

Deng X, He G, Liu J, Luo F, Peng X, Tang S, Gao Z, Lin Q, Keller JM, Yang T, Keller ET.

Cancer Treat Rev. 2014 Jul;40(6):730-8. doi: 10.1016/j.ctrv.2014.04.003. Epub 2014 Apr 16. Review.

PMID:
24767837
[PubMed - indexed for MEDLINE]
8.

Recent developments in treatments targeting castration-resistant prostate cancer bone metastases.

Loriot Y, Massard C, Fizazi K.

Ann Oncol. 2012 May;23(5):1085-94. doi: 10.1093/annonc/mdr573. Epub 2012 Jan 20. Review.

PMID:
22267211
[PubMed - indexed for MEDLINE]
Free Article
9.

Stromal targeted therapy in bone metastatic prostate cancer: promise delivered.

Sartor O, Goeckeler W, Bruland O.

Asian J Androl. 2011 Nov;13(6):783-4. doi: 10.1038/aja.2011.120. Epub 2011 Aug 22. No abstract available.

PMID:
21857688
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Natural history and treatment of bone complications in prostate cancer.

Saad F, Clarke N, Colombel M.

Eur Urol. 2006 Mar;49(3):429-40. Epub 2006 Jan 6. Review.

PMID:
16431012
[PubMed - indexed for MEDLINE]
11.

Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.

Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M.

Expert Opin Investig Drugs. 2013 Nov;22(11):1385-400. doi: 10.1517/13543784.2013.824422. Epub 2013 Sep 12. Review.

PMID:
24024652
[PubMed - indexed for MEDLINE]
12.

Molecular evidence-based use of bone resorption-targeted therapy in prostate cancer patients at high risk for bone involvement.

Karamanolakis D, Bogdanos J, Sourla A, Milathianakis C, Tsintavis A, Lembessis P, Tenta R, Tiblalexi D, Koutsilieris M.

Mol Med. 2002 Nov;8(11):667-75. Review.

PMID:
12520083
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer.

Araujo A, Cook LM, Lynch CC, Basanta D.

Cancer Res. 2014 May 1;74(9):2391-401. doi: 10.1158/0008-5472.CAN-13-2652.

PMID:
24788098
[PubMed - indexed for MEDLINE]
14.

Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.

Goyal J, Antonarakis ES.

Cancer Lett. 2012 Oct 28;323(2):135-46. doi: 10.1016/j.canlet.2012.04.001. Epub 2012 Apr 17. Review.

PMID:
22521546
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges.

Massari F, Maines F, Modena A, Brunelli M, Bria E, Artibani W, Martignoni G, Tortora G.

Anticancer Agents Med Chem. 2013 Jul 1;13(6):872-86. Review.

PMID:
23272970
[PubMed - indexed for MEDLINE]
16.

Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.

Logothetis CJ, Navone NM, Lin SH.

Clin Cancer Res. 2008 Mar 15;14(6):1599-602. doi: 10.1158/1078-0432.CCR-07-4603. Review.

PMID:
18347159
[PubMed - indexed for MEDLINE]
Free Article
17.

Bone metastasis in prostate cancer: emerging therapeutic strategies.

Sturge J, Caley MP, Waxman J.

Nat Rev Clin Oncol. 2011 Jun;8(6):357-68. doi: 10.1038/nrclinonc.2011.67. Epub 2011 May 10. Review. Erratum in: Nat Rev Clin Oncol. 2011 Oct;8(10):568.

PMID:
21556025
[PubMed - indexed for MEDLINE]
18.

Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment.

Koeneman KS, Yeung F, Chung LW.

Prostate. 1999 Jun 1;39(4):246-61. Review.

PMID:
10344214
[PubMed - indexed for MEDLINE]
19.

Systemic therapeutic strategies for prostate cancer.

Nelson WG.

Clin Adv Hematol Oncol. 2005 Aug;3(8):619-21. No abstract available.

PMID:
16167046
[PubMed - indexed for MEDLINE]
20.

Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.

van der Horst G, van den Hoogen C, Buijs JT, Cheung H, Bloys H, Pelger RC, Lorenzon G, Heckmann B, Feyen J, Pujuguet P, Blanque R, Clément-Lacroix P, van der Pluijm G.

Neoplasia. 2011 Jun;13(6):516-25.

PMID:
21677875
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk